Risk factors for the development of acute graft-versus-host disease. results of a retrospective study
Abstract
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only radical therapy for a number of hemablastoses and hematopoietic depressions. The probability of finding a related fully compatible donor is no more than 25 %. Hematopoietic stem cell donor registries increase the chances of finding an unrelated donor. Taking into account the increase in alloHSCT due to unrelated fully and partially compatible donors, there is a need to identify additional risk factors for the development of post-transplant complications, such as acute graftversus-host disease (aGVHD) in order to select an adequate immunosuppression regimen after alloHSCT.This article presents the results of a retrospective analysis of risk factors for the development of aGVHD based on the study of clinical and demographic indicators of recipients, as well as laboratory and demographic characteristics of donors and cellular characteristics of the graft.
About the Authors
O. Nechay
Минский научно-практический центр хирургии, трансплантологии и гематологии
Belarus
Belarus
N. Milanovich
Минский научно-практический центр хирургии, трансплантологии и гематологии
Belarus
Belarus
A. Dziuba
Минский научно-практический центр хирургии, трансплантологии и гематологии
Belarus
Belarus
O. Morozova
Минский научно-практический центр хирургии, трансплантологии и гематологии
Belarus
Belarus
Y. Strongin
Минский научно-практический центр хирургии, трансплантологии и гематологии
Belarus
Belarus
References
1. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) / A. Bacigalupo [et al.] // Blood. — 2001. — Vol. 98, № 10. — P. 2942—2947.
2. Ferrara, J. Graft vs. Host Disease / J. Ferrara, H. J. Deeg, K. R. Cooke. — Taylor & Francis, 2004. — 672 p.
3. Allogeneic bone marrow transplantation for acute leukemia refrac-tory to induction chemotherapy / A. R. Zander [et al.] // Cancer. — 1985. — Vol. 56, № 6. — P. 1374 —1379.
4. Prognostic value of response after upfront therapy for acute GVHD / R. M. Saliba [et al.] // Bone Mar-row Transplant. — 2012. — № 47 (1). — P. 125 —131.
5. Methotrexate and cyclosporine versus cyclosporine alone for prophylax-is of graft-versushost disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial / R. Storb [et al.] // Blood. — 1989. — Vol. 73, № 6. — P. 1729 —1734.
6. European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity sur-vey report / J. R. Passweg [et al.] // Bone Marrow Transplant. — 2018. — № 53 (9). — P. 1139—1148.
7. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria / M. E. Flowers [et al.] // Blood. — 2011. — Vol. 117, № 11. — P. 3214 —3219.
Review
For citations:
Nechay O., Milanovich N., Dziuba A., Morozova O., Strongin Y. Risk factors for the development of acute graft-versus-host disease. results of a retrospective study. Healthcare. 2024;1(11):13-17. (In Russ.)
Views:
11
Email this article 